ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock Has Average Target Price of $31.55 According to Brokerages

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have been given a consensus recommendation of “Moderate Buy” by the eighteen ratings firms that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $31.55.

Several brokerages recently commented on ACAD. UBS Group downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $49.00 to $23.00 in a research note on Tuesday, October 13th. Canaccord Genuity Group increased their price target on shares of ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Stifel Nicolaus raised their price target on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a report on Tuesday, July 21st. Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, September 23rd. Finally, Wall Street Zen downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 4th.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock opened at $18.28 on Friday. The business’s 50 day simple moving average is $22.39 and its two-hundred day simple moving average is $23.49. The stock has a market capitalization of $3.16 billion, a P/E ratio of 8.66 and a beta of 0.87. ACADIA Pharmaceuticals has a one year low of $15.85 and a one year high of $30.96.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.11. ACADIA Pharmaceuticals had a return on equity of 8.90% and a net margin of 30.13%. The firm had revenue of $342.30 million during the quarter, compared to the consensus estimate of $332.58 million. During the same quarter in the previous year, the company posted $0.42 earnings per share. The business’s revenue was up 22.8% on a year-over-year basis. Sell-side analysts expect that ACADIA Pharmaceuticals will post 0.76 earnings per share for the current fiscal year.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Acadia said it remains confident in its defense of the patent covering the 34 mg Nuplazid capsule. The Federal Circuit has heard oral arguments in the appeal of a district court decision that upheld the patent, and coverage reported a positive share-price reaction. A favorable outcome could help protect the product from patent challenges, though the court’s ruling is still months away. Acadia comment on Nuplazid patent appeal Acadia gains after oral arguments
• Neutral Sentiment: Acadia plans to present remlifanserin data at the 2026 Clinical Trials on Alzheimer’s Disease conference. The presentation could offer a pipeline update, but no study results were included in the announcement. Remlifanserin presentation announcement
• Neutral Sentiment: A report says Acadia cut its 2026 R&D guidance, but the available headline does not give the size or reason for the change. The implications for pipeline progress and spending are therefore unclear. Report on 2026 R&D guidance
• Negative Sentiment: The patent dispute remains a risk: the Federal Circuit has not yet ruled, and the decision is not expected until the first half of 2027. Patent appeal timing

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Mark Schneyer sold 3,321 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $20.88, for a total transaction of $69,342.48. Following the transaction, the executive vice president directly owned 71,322 shares of the company’s stock, valued at approximately $1,489,203.36. The trade was a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 26.20% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Nykredit A S bought a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $38,000. Meeder Asset Management Inc. purchased a new position in ACADIA Pharmaceuticals during the third quarter valued at $40,000. Integrated Wealth Concepts LLC bought a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter valued at $50,000. Global Retirement Partners LLC bought a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter valued at $64,000. Finally, GAMMA Investing LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 15.6% during the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 402 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.